Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE1
47 participants
INTERVENTIONAL
2014-03-25
2014-07-07
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Bioavailability of BMS-626529 in Healthy Subjects From Prototype Low Dose Extended Release Formulations (Part 1) and Prototype Extended Release Multi-particulate Formulations (Part 2) of BMS-663068 Relative to 600 mg Extended Release Tablet
NCT02508064
Absolute Bioavailability of BMS-626529 After Oral and Intravenous Dosing
NCT02805556
An Investigational Study to Evaluate Experimental Medication BMS-986165 Given as a Tablet and Solution in Healthy Male Participants
NCT03739788
Study to Assess Relative Bioavailability of BMS-986435 Formulations in Healthy Adult Participants
NCT06577259
A Study to Assess the Relative Bioavailability of Tablet Formulations of GSK2248761 in Healthy Adult Subjects. SGN114435
NCT01209117
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
OTHER
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Cohort 1 Arm ABDC: BMS-955176 (Treatment A, B, D and C)
BMS-955176 single dose by mouth as specified
BMS-955176
BMS-955176
Cohort 1 Arm BCDA: BMS-955176 (Treatment B, C, D and A)
BMS-955176 single dose by mouth as specified
BMS-955176
BMS-955176
Cohort 1 Arm DABC: BMS-955176 (Treatment D, A, B and C)
BMS-955176 single dose by mouth as specified
BMS-955176
BMS-955176
Cohort 1 Arm CDAB: BMS-955176 (Treatment C, D, A and B)
BMS-955176 single dose by mouth as specified
BMS-955176
BMS-955176
Cohort 2 Arm EFGH: BMS-955176 (Treatment E, F, G and H)
BMS-955176 single dose by mouth as specified
BMS-955176
BMS-955176
Cohort 2 Arm FGHE: BMS-955176 (Treatment F, G, H and E)
BMS-955176 single dose by mouth as specified
BMS-955176
BMS-955176
Cohort 2 Arm HEFG: BMS-955176 (Treatment H, E, F and G)
BMS-955176 single dose by mouth as specified
BMS-955176
BMS-955176
Cohort 2 Arm GHEF: BMS-955176 (Treatment G, H, E and F)
BMS-955176 single dose by mouth as specified
BMS-955176
BMS-955176
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
BMS-955176
BMS-955176
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Body mass index (BMI) of 18.0 to 32.0 kg/m2, inclusive. BMI = Weight (kg) / \[height (m)\]2
* Men and women, ages 18 to 50 years, inclusive
* Women must not be of childbearing potential, must not be breastfeeding
Exclusion Criteria
* History of cardiac disease or clinically significant cardiac arrhythmias
* Current or recent (within 3 months of study drug administration) gastrointestinal disease
* Any major surgery within 4 weeks of study drug administration
* Any gastrointestinal surgery (including cholecystectomy) that could impact upon the absorption of study drug
18 Years
50 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
GlaxoSmithKline
INDUSTRY
ViiV Healthcare
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
GSK Clinical Trials
Role: STUDY_DIRECTOR
ViiV Healthcare
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
GSK Investigational Site
Nottingham, , United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2013-004896-10
Identifier Type: EUDRACT_NUMBER
Identifier Source: secondary_id
AI468-034
Identifier Type: OTHER
Identifier Source: secondary_id
206740
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.